Achillion Pharmaceuticals (NASDAQ:ACHN) Stock Passes Above Two Hundred Day Moving Average of $4.12

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.12 and traded as high as $6.23. Achillion Pharmaceuticals shares last traded at $6.18, with a volume of 45,161 shares.

Several equities analysts recently commented on ACHN shares. Leerink Swann cut Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $6.30 target price for the company. in a research report on Friday, October 18th. Svb Leerink cut Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $5.00 to $6.30 in a research report on Friday, October 18th. JMP Securities cut Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. ValuEngine upgraded Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 16th. Finally, Zacks Investment Research cut Achillion Pharmaceuticals from a “hold” rating to a “sell” rating and set a $4.75 target price for the company. in a research report on Tuesday, August 27th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $4.96.

The business has a fifty day moving average price of $5.94 and a 200-day moving average price of $4.12. The company has a current ratio of 8.96, a quick ratio of 8.96 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $869.71 million, a PE ratio of -12.12 and a beta of 1.63.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. On average, equities analysts anticipate that Achillion Pharmaceuticals, Inc. will post -0.59 earnings per share for the current fiscal year.

In other news, Director David Scheer sold 10,485 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $6.31, for a total value of $66,160.35. Following the completion of the sale, the director now owns 40,000 shares of the company’s stock, valued at approximately $252,400. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Joseph Truitt sold 133,484 shares of the business’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $6.37, for a total value of $850,293.08. Following the completion of the sale, the chief executive officer now directly owns 103,734 shares of the company’s stock, valued at approximately $660,785.58. The disclosure for this sale can be found here. 4.58% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Achillion Pharmaceuticals by 142.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,227 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 4,247 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its stake in shares of Achillion Pharmaceuticals by 10.5% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 49,141 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 4,665 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Achillion Pharmaceuticals by 2.6% in the 3rd quarter. California State Teachers Retirement System now owns 213,522 shares of the biopharmaceutical company’s stock valued at $769,000 after acquiring an additional 5,330 shares during the last quarter. Virtus ETF Advisers LLC lifted its stake in shares of Achillion Pharmaceuticals by 10.0% in the 2nd quarter. Virtus ETF Advisers LLC now owns 95,598 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 8,694 shares during the last quarter. Finally, Virtu Financial LLC lifted its stake in shares of Achillion Pharmaceuticals by 72.1% in the 3rd quarter. Virtu Financial LLC now owns 25,291 shares of the biopharmaceutical company’s stock valued at $91,000 after acquiring an additional 10,592 shares during the last quarter. 79.80% of the stock is owned by institutional investors.

About Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Featured Story: How are Outstanding Shares Different from Authorized Shares?

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.